Tirzepatide, also known as LY3298176, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is developed for the treatment of type 2 diabetes and has shown significant efficacy in glucose control and weight loss compared to other treatments like Dulaglutide.
This peptide features a molecular formula of C225H348N48O68 and appears as a white lyophilized powder. With a high affinity for GIP receptors, tirzepatide mimics natural GIP actions, contributing to its effectiveness in reducing hyperglycemia. It is designed for once-weekly administration and has received FDA Fast Track designation for obesity treatment.
Clinical trials, such as SURMOUNT-1, have demonstrated substantial weight loss results: an average of 15% with a 5mg dose, 19.5% with a 10mg dose, and 20.9% with a 15mg dose over 72 weeks. This makes tirzepatide a promising option for research in metabolic disorders.
Our product is supplied in vials of 10mg, 20mg, or 30mg, packaged securely to ensure stability and purity. It is intended for research use only and not for personal consumption. Proper storage guidelines include keeping the peptide in a cold, dry, dark place and avoiding repeated freezing and thawing.